|Classification and external resources|
|NCI||C3150 Kidney cancer|
|Patient UK||Kidney cancer|
The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed.
The different types of kidney cancer (such as RCC and UCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and UCC accounts the majority of the remainder.
In addition to renal cell carcinoma and renal pelvis carcinoma, other, less common types of kidney cancer include:
- Squamous cell carcinoma
- Juxtaglomerular cell tumor (reninoma)
- Renal oncocytoma
- Bellini duct carcinoma
- Clear-cell sarcoma of the kidney
- Mesoblastic nephroma
- Wilms' tumor, usually is reported in children under the age of 5.
- Mixed epithelial stromal tumor
Rarely, some other types of cancer and potentially cancerous tumors that more usually originate elsewhere can originate in the kidneys. These include:
- Clear cell adenocarcinoma
- Transitional cell carcinoma
- Inverted papilloma
- Renal lymphoma
- Carcinoid tumor of the renal pelvis
Cancer in the kidney may also be secondary, the result of metastasis from a primary cancer elsewhere in the body.
Signs and symptoms
The most common signs and symptoms of kidney cancer are a mass in the abdomen and/or blood in the urine (or hematuria). Other symptoms may include tiredness, loss of appetite, weight loss, a high temperature and heavy sweating, and persistent pain in the abdomen. However, many of these symptoms can be caused by other conditions, and there may also be no signs or symptoms in a person with kidney cancer, especially in the early stages of the disease.
Factors that increase the risk of kidney cancer include smoking, which can double the risk of the disease; regular use of NSAIDs such as ibuprofen and naproxen, which may increase the risk by 51% or may not; obesity; faulty genes; a family history of kidney cancer; having kidney disease that needs dialysis; being infected with hepatitis C; and previous treatment for testicular cancer or cervical cancer.
Kidney cancer originates in the kidney in two principal locations: the renal tubule and the renal pelvis. Most cancers in the renal tubule are renal cell carcinoma and clear cell adenocarcinoma. Most cancers in the renal pelvis are transitional cell carcinoma.
Treatment for kidney cancer depends on the type and stage of the disease. Surgery is typically the mainstay of treatment and it usually doesn't involve chemotherapy and radiotherapy, as kidney cancers often do not respond to these treatments.
If the cancer has not spread, it will usually be removed by surgery. Sometimes this involves removing the whole kidney, which is called nephrectomy but most tumors are amenable to partial nephrectomy which is removing of the kidney tumor only and preserving the remaining normal kidney. Unfortunately, surgery is not always possible - for example the patient may have other medical conditions that prevent it, or the cancer may have spread around the body and doctors may not be able to remove it. There is currently no evidence that body-wide medical therapy after surgery where there is no known residual disease, that is, adjuvant therapy, helps to improve survival in kidney cancer.
If the cancer can't be cured with surgery, sometimes doctors may use other techniques such as cryotherapy (freezing the tumour away) or radiofrequency ablation (burning the tumour away). However these are not yet used as standard treatments for kidney cancer. Other treatment options include biological therapies (drug treatments that use natural substances from the body) such as Everolimus (Afinitor), Temsirolimus (Torisel), Sorafenib (Nexavar), Sunitinib (Sutent), and Axitinib (Inlyta), the use of immunotherapy including interferon and interleukin-2. Immunotherapy has the potential to induce complete remissions or durable partial remissions in some patients, although it works in only about 10 to 15% of patients.
In Wilms' tumor (a type of kidney cancer that affects children), chemotherapy, radiotherapy and surgery are the accepted treatments, depending on the stage of the disease when it is diagnosed. Other rare forms of kidney cancer are not discussed here.
IMA901 is used to treat patients with cancer of the kidneys. It is composed of ten synthetic tumor-associated peptides (TUMAPs), which activate the body's own killer T-cells against the tumor. Unlike chemotherapy, this process targets the body's immune responses and mobilizes them to attack the cancer.
The majority of kidney cancers reported in children are Wilms' tumors. These tumors can begin to grow when a fetus is still developing in the uterus, and may not cause problems until the child is a few years old. Wilms' tumor is most common in children under the age of 5, but can rarely be diagnosed in older children or in adults. It is still not clear what causes most Wilms' tumors. The most common symptoms are swelling of the abdomen and blood in the child's urine.
Around 208,500 new cases of kidney cancer are diagnosed in the world each year, accounting for just under 2% of all cancers. The highest rates are recorded in Northern America and the lowest rates in Asian and African regions.
The United States' NIH estimates for 2013 around 64,770 new cases of kidney cancer and 13,570 deaths from the disease.
The incidence of kidney cancer is also increasing in the United States. This is thought to be a real increase, not only due to changes in the way the disease is diagnosed.
The most recent estimates of incidence of kidney cancer suggest that there are 63,300 new cases annually in the EU25. In Europe, kidney cancer accounts for nearly 3% of all cancer cases.
Kidney cancer is the eighth most common cancer in the UK (around 10,100 people were diagnosed with the disease in 2011), and it is the fourteenth most common cause of cancer death (around 4,300 people died in 2012).
- Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH (February 2008). "[Guideline 'Renal cell carcinoma']". Ned Tijdschr Geneeskd (in Dutch; Flemish) 152 (7): 376–80. PMID 18380384.
- "SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer". NCI. Retrieved 18 June 2014.
- Thyavihally YB, Tongaonkar HB, Desai SB (September 2005). "Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report". Int Semin Surg Oncol 2: 18. doi:10.1186/1477-7800-2-18. PMC 1215508. PMID 16150156.
- Nzegwu MA, Aligbe JU, Akintomide GS, Akhigbe AO (May 2007). "Mature cystic renal teratoma in a 25-year-old woman with ipsilateral hydronephrosis, urinary tract infection and spontaneous abortion". Eur J Cancer Care (Engl) 16 (3): 300–2. doi:10.1111/j.1365-2354.2006.00755.x. PMID 17508953.
- Chiu KC, Lin MC, Liang YC, Chen CY (2008). "Renal carcinosarcoma: case report and review of literature". Ren Fail 30 (10): 1034–9. doi:10.1080/08860220802403192. PMID 19016157.
- Kuroda N, Katto K, Tamura M, Shiotsu T, Hes O, Michal M, Nagashima Y, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH (January 2008). "Carcinoid tumor of the renal pelvis: consideration on the histogenesis". Pathol. Int. 58 (1): 51–4. doi:10.1111/j.1440-1827.2007.02188.x. PMID 18067641.
- Symptoms of kidney cancer : Cancer Research UK : CancerHelp UK
- Katie Charles (January 19, 2011). "Kidney cancer: Innovative new treatments boost survival rates for cancer patients: Daily Checkup with Michael Palese". New York Daily News. Retrieved February 23, 2011.
- "Commonly Used Pain Pills Increase Kidney Cancer Risk in Study". Bloomberg.
- Lipworth, Loren; Robert E. Tarone; Joseph K McLaughlin (13 December 2005). "The Epidemiology of Renal Cell Carcinoma". Journal of Urology 176 (6): 2353–235. doi:10.1016/j.juro.2006.07.130. PMID 17085101. Retrieved 2012-07-15.
- Cheungpasitporn, W; Thongprayoon C; O'Corragain OA; Edmonds PJ; Ungprasert P; Kittanamongkolchai W; Erickson SB (9 September 2014). "The Risk of Kidney Cancer in Patients with Kidney Stones: A Systematic Review and Meta-analysis". QJM. doi:10.1093/qjmed/hcu195. PMID 25208892.
- Risks and causes of kidney cancer : Cancer Research UK : CancerHelp UK
- Early stage and locally advanced kidney cancer treatment : Cancer Research UK : CancerHelp UK
- Advanced kidney cancer : Cancer Research UK : CancerHelp UK
- List of treatments for kidney cancer
- NCCN kidney cancer guidelines
- Biological therapy for kidney cancer : Cancer Research UK : CancerHelp UK
- Jonasch, Eric; Messner, Carolyn (August 2012). "CancerCare Connect - Treatment Update: Kidney Cancer". Cancer Care, Inc. Retrieved 2012-08-29.
- Wilms' tumour (kidney cancer in children) : Cancer Research UK : CancerHelp UK
- Lindblad, P. and Adami H.O, Kidney Cancer, in Textbook of Cancer.
- GLOBOCAN 2002, Cancer Incidence, Mortality and Prevalence Worldwide 2002 estimates. 2006.
- "Cancer of the Kidney and Renal Pelvis - SEER Stat Fact Sheets". National Cancer Institute, U.S. National Institutes of Health. Retrieved 2013-02-07.
- Lynch, Charles F.; West, Michele M.; Davila, Jessica A.; Platz, Charles E. (2007). "Chapter 24: Cancers of the Kidney and Renal Pelvic". In Ries, LAG; Young, JL; Keel, GE; Eisner, MP; Horner, M-J. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 193–202.
- Ferlay J. et al. (2007). "Estimates of the cancer incidence and mortality in Europe in 2006". Annals of Oncology 18 (3): 581–92. doi:10.1093/annonc/mdl498.
- "Kidney cancer statistics". Cancer Research UK. Retrieved 27 October 2014.
- "U.S. NIH - Cancer of the Kidney and Renal Pelvis - Statistics".
- Clinically reviewed kidney cancer information for patients, from Cancer Research UK
- UK kidney cancer statistics from Cancer Research UK
- Cancer.Net: Kidney Cancer